Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Addition of Darolutamide to First Line Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): a Randomized Open Label Phase II Trial

NCT06401980 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT06401980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06401980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Addition of Darolutamide to First Line Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): a Randomized Open Label Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
October 22, 2024
Completion date
September 30, 2030
Enrollment
162 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer